Videos de Conceptos Relacionados
01:22Chronic Obstructive Pulmonary Disease
1.5K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.5K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
3.0K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.0K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.1K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.9K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.9K
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K
01:20COPD: Pathogenesis and Clinical Features
589
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
589
También podría leer
Artículos Relacionados
Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.
Ordenar por
Same author
Diagnostic criteria for invasive pulmonary aspergillosis in COPD patients.
American journal of respiratory and critical care medicine·2026
Same author
Summary of Research: Dupilumab for Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Pooled Analysis of Two Phase 3, Randomised, Double-Blind, Placebo-Controlled Trials.
Pulmonary therapy·2026
Same author
Z-scores for Spirometry Interpretation: Implications for Classifying Impairments in Lung Function.
Annals of the American Thoracic Society·2026
Same author
The Association of Race and Ethnicity with Six-Minute Walk Distance: The Multi-Ethnic Study of Atherosclerosis.
Ethnicity & disease·2026
Same author
Association Between Chronic PM2.5 Exposure and CT-Detected Lung Abnormalities in the SPIROMICS Cohort.
Annals of the American Thoracic Society·2026
Same author
Deep learning-based CT-derived vertebral bone mineral density and metformin therapy: a longitudinal study in the Multi-Ethnic Study of Atherosclerosis.
Skeletal radiology·2026
Same journal
Assisted dying and the silencing of medicine's next generation.
Lancet (London, England)·2026
Same journal
Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.
Lancet (London, England)·2026
Same journal
Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.
Lancet (London, England)·2026
Same journal
[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.
Lancet (London, England)·2026
Same journal
Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.
Lancet (London, England)·2026
Video Experimental Relacionado
Updated: Sep 24, 2025
04:03
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
918
Enfermedad pulmonar obstructiva crónica
Stephanie A Christenson1, Benjamin M Smith2, Mona Bafadhel3
1Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California San Francisco, San Francisco, CA, USA.
Lancet (London, England)
|May 9, 2022
Resumen
La enfermedad pulmonar obstructiva crónica (EPOC) es un problema de salud mundial importante. Los avances recientes en la comprensión de las causas, el diagnóstico y el tratamiento ofrecen la esperanza de mejores resultados para los pacientes.
Más Videos Relacionados
Área de la Ciencia:
- Medicina de los pulmones
- Epidemiología
- Fisiopatología
Sus antecedentes:
- La enfermedad pulmonar obstructiva crónica (EPOC) es una de las principales causas de morbilidad y mortalidad en todo el mundo.
- La exposición a partículas nocivas inhaladas, como el humo del tabaco y los contaminantes, es una de las principales causas de la EPOC.
- Cada vez se reconocen más los factores del curso de la vida que influyen en el desarrollo y la progresión de la EPOC.
Objetivo del estudio:
- Revisar los avances recientes en la epidemiología, fisiopatología, diagnóstico y tratamiento de la EPOC.
- Destacar el impacto de las innovaciones en la óptica y las imágenes en la investigación de la EPOC.
- Discutir las implicaciones del COVID-19 en las personas con EPOC.
Principales métodos:
- Revisión de la literatura científica reciente y los avances en la investigación de la EPOC.
- Integración de los hallazgos de las técnicas ómicas y de imágenes.
- Análisis de datos epidemiológicos y resultados de ensayos clínicos.
Principales resultados:
- Las innovaciones en omics e imágenes proporcionan una visión más profunda de la patobiología de la EPOC.
- Las estrategias basadas en biomarcadores están mejorando la orientación de las terapias de EPOC existentes.
- El COVID-19 agrava los riesgos para los pacientes con EPOC y interrumpe la prestación de atención médica.
Conclusiones:
- Los avances en la comprensión de la EPOC están allanando el camino para mejorar las estrategias de prevención, diagnóstico y tratamiento.
- Los enfoques de medicina personalizada que utilizan biomarcadores son prometedores para el manejo de la EPOC.
- El impacto continuo de COVID-19 requiere estrategias de atención médica adaptativas para los pacientes con EPOC.